title: Is it time for medical therapy for aortic valve disease?
abstract: Calcific aortic stenosis is the most common indication for surgical valve replacement. Currently there are no medical therapies approved for the treatment of this disease. This review will summarize the clinical and experimental studies published over the past 5 years that indicate that medical therapy may be an option for this patient population.
authors.affiliation: Northwestern University Feinberg School of Medicine, Feinberg Cardiovascular Research Institute, 303 E Chicago Avenue, Tarry 12-703, Chicago, IL 60611, USA. n-rajamannan@northwestern.edu.
authors.forename: Nalini M
authors.initials: NM
authors.lastname: Rajamannan
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001024:Aortic Valve Stenosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D000069059:Atorvastatin; D001707:Biopsy, Needle; D002114:Calcinosis / Q000473:pathology* / Q000601:surgery; D018849:Controlled Clinical Trials as Topic; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011758:Pyrroles / Q000627:therapeutic use*; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D011758:Pyrroles; D000069059:Atorvastatin